目的 探討心通口服液聯(lián)合氨氯地平治療冠心病心絞痛的臨床療效。方法 選取2018年10月—2019年12月在天津市第一中心醫(yī)院就診的冠心病心絞痛患者226例，隨機分為對照組和治療組，每組各113例。對照組口服苯磺酸左氨氯地平片，5 mg/次，1次/d。治療組在對照組的基礎(chǔ)上口服心通口服液，10～20 mL/次，3次/d。兩組患者治療2個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者西雅圖調(diào)查量表（SAQ）評分、血管內(nèi)皮生長因子水平、心功能、心絞痛發(fā)作頻率和持續(xù)時間。結(jié)果 治療后，對照組臨床有效率為80.53%，顯著低于治療組的95.58%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者SAQ評分顯著高于治療前（P<0.05），且治療組患者SAQ評分明顯高于對照組（P<0.05）。治療后，兩組患者血管內(nèi)皮生長因子水平、左室射血分數(shù)（LVEF）和心輸出量（CO）顯著高于治療前（P<0.05），體血管阻力（SVR）和胸腔液體含量（TFC）顯著低于治療前（P<0.05），且治療后治療組患者這些指標(biāo)水平明顯好于對照組（P<0.05）。治療后，兩組心絞痛發(fā)作頻率和心絞痛持續(xù)時間明顯下降（P<0.05），且治療組的心絞痛發(fā)作頻率和心絞痛持續(xù)時間顯著低于對照組（P<0.05）。結(jié)論 心通口服液聯(lián)合氨氯地平治療冠心病心絞痛可改善患者心功能和血管內(nèi)皮生長因子水平，臨床療效顯著，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Xintong Oral Liquid combined with amlodipine in treatment of angina pectoris of coronary heart disease. Methods Patients (226 cases) with angina pectoris of coronary heart disease in Tianjin First Central Hospital from October 2018 to December 2019 were randomly divided into control and treatment groups, and each group had 113 cases. Patients in the control group were po administered with Levamlodipine Besylate Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group, 10 — 20 mL/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the SAQ scores, the VEGF level, cardiac function, the frequency and duration of angina pectoris in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.53%, which was significantly lower than 95.58% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the SAQ scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than that in the control group (P<0.05). After treatment, the VEGF level, LVEF and CO in two groups were significantly increased (P<0.05), but the SVR and TFC were significantly decreased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Xintong Oral Liquid combined with amlodipine can improve the cardiac function and VEGF level, has a significant clinical effect and a certain clinical application value.

R972